¿Cuáles son los avances de la genómica y la proteómica en el tamizaje y/o predicción de la preeclampsia?

  • Augusto Valderrama-Aguirre
  • Dahiana Gallo
  • Rodrigo Cifuentes

Resumen

Introducción: la preeclampsia constituye una causa importante de morbimortalidad materna y perinatal en el mundo. Su etiopatogenia es aún un enigma; sin embargo, los avances en genómica y proteómica prometen la identificación temprana de la enfermedad o del riesgo de padecerla.

Objetivo: hacer una reflexión sobre los avances más promisorios de la genómica y proteómica, en el tamizaje y/o predicción de la preeclampsia.

Conclusiones: dos polimorfismos funcionales, uno en el gen ACE (I/D) y otro en el gen COMT (Val158Met), poseen los resultados más promisorios para cumplir con el objetivo de identificar genéticamente a las mujeres con mayor riesgo de desarrollar preeclampsia durante un embarazo. Por su parte, la proteómica ha identificado a la SERPINA-1 como un biomarcador útil para detectar en la orina de las embarazadas que estén desarrollando la preeclampsia, con al menos 10 semanas de antelación a las manifestaciones clínicas de la misma y la necesidad de finalizar el embarazo. En conjunto, estos avances llevados a la práctica clínica podrían reducir el impacto de esta patología en la salud materna.

Descargas

La descarga de datos todavía no está disponible.

Biografía del autor/a

Augusto Valderrama-Aguirre
Bacteriólogo y Laboratorista Clínico, Magíster en Ciencias Básicas Médicas Candidato a Doctor en Ciencias Biomédicas. Profesor Asociado, Departamento de Ciencias Básicas, Universidad Libre -Seccional Cali. Director Instituto de Investigaciones Biomédicas (IIB). Cali (Colombia).
Dahiana Gallo
Médico y Cirujano. Residente III año Ginecología y Obstetricia, Universidad Libre-Seccional Cali. Asistente Investigación Grupo Interinstitucional de Ginecología y Obstetricia (GIGyO). Cali (Colombia).
Rodrigo Cifuentes
Médico y Cirujano. Especialista Ginecología y Obstetricia. Doctor en Biología de la Reproducción. Profesor Titular y Emérito de Ginecología y Obstetricia Universidad del Valle. Director del Posgrado de Ginecología y Obstetricia, Universidad Libre-Seccional Cali. Maestro Latinoamericano de Ginecología y Obstetricia FLASOG. Director del Grupo Interinstitucional de Ginecología y Obstetricia (GIGyO). Cali (Colombia).

Referencias bibliográficas

Duley L. The global impact of pre-eclampsia and eclampsia. Seminars in perinatology 2009;33:130-7.

Khan KS, Wojdyla D, Say L, Gulmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet 2006;367:1066-74.

Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet 2010;376:631-44.

Yngvadottir B, Macarthur DG, Jin H, Tyler-Smith C. The promise and reality of personal genomics. Genome Biol 2009;10:237.

Niculescu AB, Le-Niculescu H. Convergent Functional Genomics: what we have learned and can learn about genes, pathways, and mechanisms. Neuropsychopharmacology 2009;35:355-6.

Silberring J, Ciborowski P. Biomarker discovery and clinical proteomics. Trends Analyt Chem 2010;29:128.

Latterich M, Abramovitz M, Leyland-Jones B. Proteomics: new technologies and clinical applications. Eur J Cancer 2008;44:2737-41.

Nakamura K, Aebersold R, Bairoch A, et al. [From genome to proteome--aim of human proteomics]. Seikagaku 2004;76:1271-4.

Levinson SS. Clinical validation of biomarkers for predicting risk. Adv Clin Chem 2009;48:1-25.

Chesley LC, Annitto JE, Cosgrove RA. The familial factor in toxemia of pregnancy. Obstet Gynecol 1968;32:303-11.

Benedetto C, Marozio L, Ciccone G, et al. Synergistic effect of renin-angiotensin system and nitric oxide synthase genes polymorphisms in pre-eclampsia. Acta Obstet Gynecol Scand 2007;86:678-82.

Kanasaki K, Kalluri R. The biology of preeclampsia. Kidney Int 2009;76:831-7.

Mutze S, Rudnik-Schoneborn S, Zerres K, Rath W. Genes and the preeclampsia syndrome. J Perinat Med 2008;36:38-58.

Sayed-Tabatabaei FA, Oostra BA, Isaacs A, van Duijn CM, Witteman JC. ACE polymorphisms. Circ Res 2006;98:1123-33.

Shah DM. Preeclampsia: new insights. Curr Opin Nephrol Hypertens 2007;16:213-20.

Irani RA, Xia y. The functional role of the reninangiotensin system in pregnancy and preeclampsia. Placenta 2008;29:763-71.

Mandò C, Antonazzo P, Tabano S, Zanutto S, Pileri P, Somigliana E, et al. Angiotensin-converting enzyme and adducin-1 polymorphisms in women with preeclampsia and gestational hypertension. Reprod Sci 2009;16:819-26.

Li H, Ma y, Fu Q, Wang L. Angiotensin-converting enzyme insertion/deletion (ACE I/D) and angiotensin II type 1 receptor (AT1R) gene polymorphism and its association with preeclampsia in Chinese women. Hypertens Pregnancy 2007;26:293-301.

Velloso EP, Vieira R, Cabral AC, Kalapothakis E, Santos RA. Reduced plasma levels of angiotensin-(1-7) and renin activity in preeclamptic patients are associated with the angiotensin I-converting enzyme deletion/deletion genotype. Braz J Med Biol Res 2007;40:583-90.

Fatini C, Sticchi E, Gensini F, Genuardi M, Tondi F, Gensini GF, et al. Endothelial nitric oxide synthase gene influences the risk of pre-eclampsia, the recurrence of negative pregnancy events, and the maternal-fetal flow. J Hypertens 2006;24:1823-9.

Mello G, Parretti E, Fatini C, Riviello C, Gensini F, Marchionni M, et al. Low-molecular weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women. Hypertension 2005;45:86-91.

Mello G, Parretti E, Gensini F, Sticchi E, Mecacci F, Scarselli G, et al. Maternal-fetal flow, negative events, and preeclampsia: role of ACE I/D polymorphism. Hypertension 2003;41:932-7.

Miskovic B, Sertic J, Stavljenic-Rukavina A, Stipoljev F. Association of angiotensin-converting enzyme insertion-deletion polymorphism with preeclampsia. Coll Antropol 2008;32:339-43.

Choi H, Kang Jy, Yoon HS, Han SS, Whang CS, Moon IG, et al. Association of Angiotensin-converting enzyme and angiotensinogen gene polymorphisms with preeclampsia. J Korean Med Sci 2004;19:253-7.

Gurdol F, Isbilen E, yilmaz H, Isbir T, Dirican A. The association between preeclampsia and angiotensin converting enzyme insertion/deletion polymorphism. Clin Chim Acta 2004;341:127-31.

Bai H, Liu X, Liu R, Liu y, Li M, Liu B. [Angiotensinogen and angiotensin-I converting enzyme gene variations in Chinese pregnancy induced hypertension]. Hua Xi yi Ke Da Xue Xue Bao 2002;33:233-7.

Kim YJ, Park MH, Park HS, Lee KS, Ha EH, Pang MG. Associations of polymorphisms of the angiotensinogen M235 polymorphism and angiotensin-convertingenzyme intron 16 insertion/deletion polymorphism with preeclampsia in Korean women. Eur J Obstet Gynecol Reprod Biol 2004;116:48-53.

Nalogowska-Glosnicka K, Lacka B, Zychma M, Grzeszczak W, Michalski B, Poreba R, et al. [Lack of relationship between angiotensinogen gene m235t polymorphism and gene insertion/deletion (I/Dintron 16) and Pst IRFLP (P/M-intron 7) polymorphisms of the angiotensin I converting enzyme(ACE) gene and the development of H-gestosis. Preliminary results]. Pol Arch Med Wewn 1998;100:19-26.

Serrano NC, Diaz LA, Paez MC, Mesa CM, Cifuentes R, Monterrosa A, et al. Angiotensin-converting enzyme I/D polymorphism and preeclampsia risk: evidence of small-study bias. PLoS Med 2006;3:e520.

Eisenmann JC, Sarzynski MA, Glenn K, Rothschild M, Heelan KA. ACE I/D genotype, adiposity, and blood pressure in children. Cardiovasc Diabetol 2009;8:14.

Glenn KL, Du ZQ, Eisenmann JC, Rothschild MF. An alternative method for genotyping of the ACE I/D polymorphism. Mol Biol Rep 2009;36:1305-10.

Evangelos E, Thomas T, Salanti G, Loannidis J. Familybased versus unrelated case-control designs for genetic associations. PLoS Genet 2006;2:1147-55.

Evangelou E, Trikalinos TA, Salanti G, Ioannidis JP. Family-based versus unrelated case-control designs for genetic associations. PLoS Genet 2006;2:e123.

Kanasaki K, Palmsten K, Sugimoto H, Ahmad S, Hamano Y, Xie L, et al. Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature 2008;453:1117-21.

Berg D, Sonsalla R, Kuss E. Concentrations of 2-methoxyoestrogens in human serum measured by a heterologous immunoassay with an 125I-labelled ligand. Acta Endocrinol (Copenh) 1983;103:282-8.

Tunbridge EM, Harrison PJ, Weinberger DR. Catechol-omethyltransferase, cognition, and psychosis: Val158Met and beyond. Biol Psychiatry 2006;60:141-51.

Sata F, Yamada H, Suzuki K, Saijo Y, Yamada T, Minakami H, et al. Functional maternal catechol-O-methyltransferase polymorphism and fetal growth restriction. Pharmacogenet Genomics 2006;16:775-81.

Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ 2003;327:955-60.

Barnea ER, Fakih H, Oelsner G, Walner S, DeCherney AH, Naftolin F. Effect of antihypertensive drugs on catechol-O-methyltransferase and monoamine oxidase activity in human term placental explants. Gynecol Obstet Invest 1986;21:124-30.

Zamorski MA, Green LA. NHBPEP report on high blood pressure in pregnancy: a summary for family physicians. Am Fam Physician 2001;64:263-70.

Lindheimer MD, Katz AI. The normal and diseased kidney in pregnancy. En: Diseases of the Kidney and Urinary Tract. 7th edition ed. Philadelphia: Lippincott, Williams and Wilkins; 2001. p. 2129-65.

Ferrazzani S, Caruso A, De Carolis S, Martino IV, Mancuso S. Proteinuria and outcome of 444 pregnancies complicated by hypertension. Am J Obstet Gynecol 1990;162:366-71.

Buhimschi IA, Zhao G, Funai E, Harris N, Sasson IE, Bernstein IM, et al. Proteomic profiling of urine identifies specific fragments of Serpina-1 and Albumni as biomarkers of Preeclampsia. Am J Obstet Gynecol 2008;199:551.e1-16.

Wang CC, Yim KW, Poon TC, Choy KW, Chu CY, Lui WT, et al. Innate immune response by ficolin binding in apoptotic placenta is associated with the clinical syndrome of preeclampsia. Clin Chem 2007;53:42-52.

Sun LZ, yang NN, De W, Xiao YS. Proteomic analysis of proteins differentially expressed in preeclamptic trophoblasts. Gynecol Obstet Invest 2007;64:17-23.

Vascotto C, Salzano AM, D'Ambrosio C, Fruscalzo A, Marchesoni D, di Loreto C, et al. Oxidized transthyretin in amniotic fluid as an early marker of preeclampsia. J Proteome Res 2007;6:160-70.

ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 2002;99:159-67.

Gharesi-Fard B, Zolghadri J, Kamali-Sarvestani E. Proteome differences of placenta between pre-eclampsia and normal pregnancy. Placenta 2009;31:121-5.

Publicado
2011-03-30
Cómo citar
1.
Valderrama-Aguirre A, Gallo D, Cifuentes R. ¿Cuáles son los avances de la genómica y la proteómica en el tamizaje y/o predicción de la preeclampsia?. Rev. Colomb. Obstet. Ginecol. [Internet]. 30 de marzo de 2011 [citado 24 de julio de 2021];62(1):64-0. Disponible en: https://revista.fecolsog.org/index.php/rcog/article/view/239
Sección
Artículo de Reflexión
Crossref Cited-by logo